Stimulation of osteoprotegerin production is responsible for osteosclerosis in mice overexpressing TPO

Blood

Volumn 101, Issue 8, 2003, Pages 2983-2989

  Chagraoui, Hédia ^b   Tulliez, Micheline ^b   Smayra, Tarek ^b   Komura, Emiko ^b   Giraudier, Stéphane ^b   Yun, Theodore ^b   Lassau, Nathalie ^b   Vainchenker, William ^a   Wendling, Françoise ^b  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

OSTEOPROTEGERIN; THROMBOPOIETIN; TRANSFORMING GROWTH FACTOR BETA1; CELL RECEPTOR; GLYCOPROTEIN; HYBRID PROTEIN; TGFB1 PROTEIN, MOUSE; TNFRSF11B PROTEIN, MOUSE; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW CELL; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GENE OVEREXPRESSION; HEMATOPOIETIC CELL; MALE; MOUSE; MYELOFIBROSIS; MYELOPROLIFERATIVE DISORDER; NONHUMAN; OSTEOSCLEROSIS; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN SYNTHESIS; WILD TYPE; ANIMAL; BIOSYNTHESIS; BLOOD; BONE; BONE MARROW TRANSPLANTATION; C57BL MOUSE; CELL CULTURE; COMPARATIVE STUDY; DISEASE MODEL; GENE EXPRESSION REGULATION; GENE VECTOR; GENETIC TRANSDUCTION; GENETICS; METABOLISM; MOUSE MUTANT; OSTEOCLAST; OSTEOPOROSIS; PATHOLOGY; PHYSIOLOGY; RADIATION CHIMERA; RETROVIRUS;

ANIMALS; BONE AND BONES; BONE MARROW TRANSPLANTATION; CELLS, CULTURED; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION; GENETIC VECTORS; GLYCOPROTEINS; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MYELOFIBROSIS; MYELOPROLIFERATIVE DISORDERS; OSTEOCLASTS; OSTEOPOROSIS; OSTEOPROTEGERIN; OSTEOSCLEROSIS; RADIATION CHIMERA; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, TUMOR NECROSIS FACTOR; RECOMBINANT FUSION PROTEINS; RETROVIRIDAE; THROMBOPOIETIN; TRANSDUCTION, GENETIC; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1;

EID: 0037606007     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2002-09-2839     Document Type: Article

References (52)

1. Ducy P, Schinke T, Karsenty G. The osteoblast: a sophisticated fibroblast under central surveillance. Science. 2000;289:1501-1504.
2. Teitelbaum S. Bone resorption by osteoclasts. Science. 2000;289:1504-1508.
3. Lecanda F, Warlow P, Sheikh S, Furlan F, Steinberg T, Civitelli R. Connexin 43 deficiency causes delayed ossification, craniofacial abnormalities, and osteoblast dysfunction. J Cell Biol. 2000;151:931-944.
4. Strewler G. Local and systemic control of the osteoblast. J Clin Invest. 2001;107:271-272.
5. Zhao G, Monier-Faugere M, Langub M, et al. Targeted overexpression of insulin-like growth factor I to osteoblasts to transgenic mice: increased trabecular bone volume without osteoblast proliferation. Endocrinology. 2000;141:2674-2682.
6. Montero A, Okada Y, Tomita M, et al. Disruption of the fibroblast growth factor-2 gene results in decreased bone mass and bone formation. J Clin Invest. 2000;105:1085-1093.
7. Centrella M, Horowitz M, Wozney J, McCarthy T. Transforming growth factor-β gene family members and bone. Endocr Rev. 1994;15:27-39.
8. Noda M, Camilliere J. In vivo stimulation of bone formation by transforming growth factor-β. Endocrinology. 1989;124:2991-2994.
9. Erlebacher A, Filvaroff E, Ye J, Derynck R. Osteoblastic responses to TGF-β during bone remodeling. Mol Biol Cell. 1998;9:1903-1918.
10. Alliston T, Choy L, Ducy P, Karsenty G, Derynck R. TGF-β-induced repression of CBFA1 by Smad3 decreases cbfa1 and osteocalcin expression and inhibits osteoblast differentiation. EMBO J. 2001;20:2254-2272.
11. Udagawa N, Takahashi N, Akatsu T, et al. Origin of osteoclasts: mature monocytes and macrophages are capable of differentiating into osteoclasts under a suitable microenvironment prepared by bone marrow-derived stromal cells. Proc Natl Acad Sci U S A. 1990;87:7260-7264.
12. Yoshida H, Hayashi S, Kunisada T, et al. The murine mutation osteopetrosis is in the coding region of the macrophage colony stimulating factor gene. Nature. 1990;345:442-444.
13. Li J, Sarosi I, Yan X, et al. RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism. Proc Natl Acad Sci U S A. 2000;97:1566-1571.
14. Lacey D, Timms E, Tan H, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell. 1998;93:165-176.
15. Simonet W, Lacey D, Dunstan C, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell. 1997;89:309-319.
16. Kong Y, Yosshida H, Sarosi I, et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature. 1999;397:315-323.
17. Dougall W, Glaccum M, Charrier K, et al. RANK is essential for osteoclast and lymph node development. Genes Dev. 1999;13:2412-2424.
18. Bucay N, Sarosi I, Dunstan C, et al. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev. 1998;12:1260-1268.
19. Takai H, Kanematsu M, Yano K, et al. Transforming growth factor-β stimulates the production of osteoprotegerin/osteoclastogenesis inhibitory factor by bone marrow stromal cells. J Biol Chem. 1998;273:27091-27096.
20. Thirunavukkarasu K, Miles R, Halladay D, et al. Stimulation of osteoprotegerin (OPG) gene expression by transforming growth factor-beta (TGF-beta). Mapping of the OPG promoter region that mediates TGF-beta effects. J Biol Chem. 2001;276:36241-36250.
21. Kaneda T, Nojima T, Nakagawa M, et al. Endogenous production of TGF-β is essential for osteoclastogenesis induced by a combination of receptor activator of NF-kB ligand and macrophage-colony stimulating factor. J Immunol. 2000;165:4254-4263.
22. Tefferi A. Myelofibrosis with myeloid metaplasia. N Engl J Med. 2000;342:1255-1265.
23. Jacobson R, Salo A, Fialkow P. Agnogenic myeloid metaplasia: a clonal proliferation of hematopoietic stem cells with secondary myelofibrosis. Blood. 1978;51:189-194.
24. Castro-Malaspina H, Rabellino E, Yen A, Nachman R, Moore M. Human megakaryocyte stimulation of bone marrow fibroblasts. Blood. 1981;57:781-787.
25. Terui T, Niitsu J, Mahara K, et al. The production of transforming growth factor-b in acute megakaryoblastic leukemia and its possible implications in myelofibrosis. Blood. 1990;75:1540-1548.
26. Reilly I, Barnett D, Dolan G, Forrest P, Eastham I, Smith A. Characterization of an acute micromegakaryocytic leukemia: evidence for the pathogenesis of myelofibrosis. Br J Haematol. 1993;83:58-62.
27. Martyre M, Romquin N, Le Bousse-Kerdiles M, et al. Transforming growth factor-beta and megakaryocytes in the pathogenesis of idiopathic myelofibrosis. Br J Haematol. 1994;88:9-16.
28. Rameshwar P, Denny T, Stein D, Gascon P. Monocyte adhesion in patients with bone marrow fibrosis is required for the production of fibrogenic cytokines: potential role for interleukin-1 and TGF-beta. J Immunol. 1994;153:2819-2830.
29. Martyre M. TGF-b and megakaryocytes in the pathogenesis of myelofibrosis in myeloproliferative disorders. Leuk Lymphoma. 1995;20:39-44.
30. Frey B, Rafii S, Teterson M, Eaton D, Crystal R, Moore M. Adenovector-mediated expression of human thrombopoietin cDNA in immune-compromised mice: insights into the pathophysiology of osteomyelofibrosis. J Immunol. 1998;160:691-699.
31. Long M, Robinson J, Ashcraft E, Mann K. Regulation of human bone marrow-derived osteoprogenitor cells by osteogenic growth factors. J Clin Invest. 1995;95:881-887.
32. Yan X-G, Lacey D, Flechter F, et al. Chronic exposure to retroviral vector encoded MGDF (mpl-ligand) induces lineage-specific growth and differentiation of megakaryocytes in mice. Blood. 1995;86:4025-4033.
33. Yan X-G, Lacey D, Hill D, Chen Y, Fletcher F, Hawley R, McNiece I. A model of myelofibrosis and osteosclerosis in mice induced by overexpressing thrombopoietin (mpl ligand): reversal of disease by bone marrow transplantation. Blood. 1996;88:402-409.
34. Villeval J-L, Cohen-Solal K, Tulliez M, et al. High thrombopoietin production by hemopoietic cells induces a fatal myeloproliferative syndrome in mice. Blood. 1997;90:4369-4383.
35. Chagraoul H, Komura E, Tulliez M, Vainchenker W, Wendling F. Prominent role of TGF-β 1 secreted by hematopoietic cells in bone marrow fibrosis induction. Blood. 2002;100:3495-3503.
36. Yun T, Tallquist M, Aicher A, et al. Osteoprotegerin, a crucial regulator of bone metabolism, also regulates B cell development and function. J Immunol. 2001;166:1482-1491.
37. Josien R, Douillard P, Guillot C, et al. A critical role for transforming growth factor-β in donor transfusion-induced allograft tolerance. J Clin Invest. 1998;102:1920-1926.
38. Chagraoui H, Giraudier S, Vainchenker W, Wendling F. Adenoviral supply of active transforming growth factor-β1 (TGF-β1) did not prevent lethality in transforming growth factor-b1-knockout embryos. Eur Cytokine Netw. 2001;12:561-567.
39. Yun T, Chaudhary P, Shu G, et al. OPG/FDCR-1, a TNF receptor family member, is expressed in lymphoid cells and is up-regulated by ligating CD40. J Immunol. 1998;161:6113-6121.
40. Kong Y, Feige U, Sarosi L, et al. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature. 1999;402:304-309.
41. Giuliani N, Bataille R, Mancini C, Lazzaretti M, Barillé S. Myeloma cells induce imbalance in the osteoprotegerin/osteoprotegerin ligand system in the human bone marrow environment. Blood. 2001;98:3527-3533.
42. Pearse R, Sordillo E, Yaccoby S, et al. Multiple myeloma disrupts the TRANCE/osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression. Proc Natl Acad Sci U S A. 2001;98:11581-11586.
43. Yanagida M, Ide Y, Toriyama M, et al. The role of transforming growth factor-beta in PEGr-HuMGDF-induced reversible myelofibrosis in rats. Br J Haematol. 1997;99:739-745.
44. Min H, Morony S, Sarosi I, et al. Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis. J Exp Med. 2000;192:463-474.
45. Murakami T, Yamamoto M, Ono K, et al. Transforming growth factor-beta 1 increases mRNA levels of osteoclastogenesis inhibitory factor in osteoblastic/stromal cells and inhibits the survival of murine osteoclast-like cells. Biochem Biophys Res Commun. 1998;252:747-752.
46. Avraham H, Vannier E, Chi S, Dinarello C, Gropman J. Cytokine gene expression and synthesis by human megakaryocytic cells. Int J Cell Cloning. 1992;10:70-79.
47. Wakikawa T, Shioi A, Hino M, et al. Thrombopoietin inhibits in vitro osteoclastogenesis from murine bone marrow cells. Endocrinology. 1997;1997:4160-4166.
48. Zhang J, Fu M, Myles D, Zhu X, Du J, Cao X, Chen Y. PDGF induces osteoprotegerin expression in vascular smooth muscle cells by multiple signal pathways. FEBS Lett. 2002;521:180-184.
49. Vidal O, Sjogren K, Eriksson B, Ljunggren O, Ohlsson C. Osteoprotegerin mRNA is increased by interleukin-1 alpha in the human osteosarcoma cell line MG-63 and in human osteoblast-like cells. Biochem Biophys Res Commun. 1998;248:696-700.
50. Lee S, Kalinowski J, Jastrzebski S, Lorenzo J. 1,25 (OH)(2) vitamin D(3)-stimulated osteoclast formation in spleen-osteoblast cocultures is mediated in part by enhanced IL-1 alpha and receptor activator of NF-kappaB ligand production in osteoblasts. J Immunol. 2002;169:2374-2380.
51. Quinn J, Itoh K, Udagawa N, et al. Transforming growth factor beta affects osteoclast differentiation via direct and indirect actions. J Bone Miner Res. 2001;16:1787-1794.
52. Vannuchi A, Bianchi L, Cellai C, et al. Development of myelofibrosis in mice genetically impaired for GATA-1 expression (GATA-1low mice). Blood. 2002;100:1123-1132.